Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?